Safety and Equivalence of a Generic Ciclopirox Olamine Cream Compared to the Reference Ciclopirox Cream 0.77% for the Treatment of Tinea Pedis

Last updated: October 11, 2021
Sponsor: Padagis LLC
Overall Status: Completed

Phase

3

Condition

Fungal Infections

Yeast Infections

Athlete's Foot (Tinea Pedis)

Treatment

N/A

Clinical Study ID

NCT00802672
CPL-302
  • Ages > 10
  • All Genders

Study Summary

The objectives of this study were to demonstrate comparable safety and efficacy of Ciclopirox Olamine Cream (Test Product) and Ciclopirox Cream 0.77% (Reference Product) in the treatment of subjects with tinea pedis, and to show the superiority of the active treatments over that of the vehicle.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male or female at least 10 years of age, and otherwise healthy
  • Clinically and mycologically confirmed diagnosis of symptomatic tinea pedis
  • In good health with no clinically significant disease that might have interfered withstudy evaluations
  • Study participant or legal guardian was willing and able to read and sign an IRBapproved ICF, which included agreement to comply with all study requirements asindicated in the protocol. For subjects 10 to 17 years of age, an assent form forminors was completed.

Exclusion

Exclusion Criteria:

  • History of hypersensitivity or allergy to ciclopirox
  • Had any skin condition that would interfere with the diagnosis or assessment of tineapedis
  • Had a history of dermatophyte infecton unresponsive to antifungal treatment
  • Had a history of alcoholism, drug abuse, or problems that would likely have made thesubject unreliable for the study
  • Had any condition or used any medication that, in the opinion of the Investigator,might have interfered with the conduct or results of the study or placed theprospective subject at increased risk
  • Was unwilling to sign the informed consent
  • Female who was pregnant or lactating

Study Design

Total Participants: 561
Study Start date:
December 01, 2003
Estimated Completion Date:
May 31, 2004